Chinese Biotech Firm Immunochina Raises $20M In Series C Round

Login to View

Chinese biotechnology company Immunochina Pharmaceuticals has raised a RMB$140 million (US$20.4 million) series C round of financing led by a syndicate of Chinese and international investors, according to a statement released on January 22.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 3 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription for $359

Enjoy comprehensive and exclusive data you can't find elsewhere!

Subscribe for $359

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in